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53BP1 plays multiple roles in mammalian DNA dam-
age repair, mediating pathway choice and facilitating
DNA double-strand break repair in heterochromatin.
Although it possesses a C-terminal BRCT2 domain,
commonly involved in phospho-peptide binding in
other proteins, initial recruitment of 53BP1 to sites
of DNA damage depends on interaction with histone
post-translational modifications—H4K20me2 and
H2AK13/K15ub—downstream of the early gH2AX
phosphorylation mark of DNA damage. We now
show that, contrary to current models, the 53BP1-
BRCT2 domain binds gH2AX directly, providing a
third post-translational mark regulating 53BP1 func-
tion. We find that the interaction of 53BP1 with
gH2AX is required for sustaining the 53BP1-depen-
dent focal concentration of activated ATM that
facilitates repair of DNA double-strand breaks in het-
erochromatin in G1.INTRODUCTION
TP53 binding protein 1 (53BP1) is a large multi-domain protein
with multiple roles in the DNA damage response (Panier and
Boulton, 2014; Zimmermann and de Lange, 2014). Following
DNA damage and activation of the DNA-damage-responsive
protein kinase ATM, 53BP1 is recruited rapidly to nuclear foci
(Schultz et al., 2000) containing the primary mark of DNA
damage—phosphorylation of Ser139 close to the C terminus of
the histone H2A variant—H2AX (Rogakou et al., 1998), generally
known as gH2AX. Although 53BP1 has a C-terminal tandem
BRCT domain (BRCT2), which in its orthologs, Saccharomyces
cerevisiae Rad9p and Schizosaccharomyces pombe Crb2, me-
diates binding to the equivalents of gH2AX (Hammet et al.,
2007; Kilkenny et al., 2008), the role of the 53BP1-BRCT2 domain
remains controversial. Although some studies indicated an inter-Cell Repaction with gH2AX (Stewart et al., 2003;Ward et al., 2003), others
have contradicted this (Stucki et al., 2005;Ward et al., 2006), and
a significant role for this domain in the DNA damage response
has been largely discounted (Bothmer et al., 2011; Callen
et al., 2013).
Current models suggest that 53BP1 recruitment to ionizing ra-
diation induced nuclear foci (IRIF) depends only indirectly on
gH2AX and is instead mediated by two other post-translational
modifications: (1) H2AK13/15-anchored ubiquitin chains (Fra-
det-Turcotte et al., 2013) generated by the E3 ubiquitin ligases
RNF8 and RNF168, which are themselves recruited by MDC1,
whose BRCT2 domain interaction with gH2AX is required for its
own recruitment (Bekker-Jensen and Mailand, 2010; Pinder
et al., 2013); and (2) direct interaction of the tandem Tudor do-
mains of 53BP1 with dimethylated H4K20 (Botuyan et al.,
2006) exposed by release of JMJD2A and L3MBTL1 following
their ubiquitylation by RNF8 and RNF168 (Acs et al., 2011; Mal-
lette et al., 2012).
We have re-examined the role of the 53BP1-BRCT2 domain
and show unambiguously that it is a competent binding module
for phosphorylated peptides with a clear specificity for the DNA-
damage marker gH2AX, and in isolation from other parts of
53BP1 is sufficient for localization to sites of DNA damage in
cells associated with gH2AX.
Structure-based mutational disruption of gH2AX binding by
53BP1 interferes with the 53BP1-dependent localization of
pATM required for repair of DNA damage in regions of hetero-
chromatin and results in a defect in the slow phase of DNA break
repair in G1. These data add a third histone post-translational
mark to the ligand repertoire of 53BP1, and a clear functional
role for phosphopeptide binding by its BRCT2 domain.RESULTS AND DISCUSSION
53BP1-BRCT2 Binds gH2AX In Vitro
Comparison of the tandem BRCT domains of 53BP1 with those
of MDC1 (Rodriguez et al., 2003; Stucki et al., 2005) and Crb2
(Kilkenny et al., 2008) shows strong conservation of residuesorts 13, 2081–2089, December 15, 2015 ª2015 The Authors 2081
Figure 1. 53BP1 BRCT2 Domain Binds gH2AX
(A) Fluorescence polarization assay (closed circle) showing binding of His6-SUMO-53BP1-BRCT2 to a fluorescein-tagged phosphopeptide (Flu-
SGGKKATQApSQEY) corresponding to the last 13 residues of gH2AX. Data are means of four replicates with error bars showing 1 SD, and the KD (1.4 mM ± 0.15)
was calculated by least-squares fitting of a one-site binding model. Removal of the phosphate group on Ser139 by addition of l-phosphatase (open circle)
abrogates the interaction. The dashed line indicates a signal level consistent with non-specific interaction.
(B) As (A) but for His6-SUMO-MDC1-BRCT2 binding to the fluorescein-tagged gH2AX phosphopeptide.
(legend continued on next page)
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implicated in specific binding of phosphorylated histone H2A
tails. To determine whether 53BP1 shared this property, we
measured the binding of the isolated 53BP1-BRCT2 segment
to a fluorescently labeled phosphopeptide (fluorescein-
SGGKKATQApSQEY) corresponding to the last 13 residues of
human gH2AX, by fluorescence polarization (see Experimental
Procedures). 53BP1-BRCT2 bound the phosphopeptide with a
KD of 1.4 mM (Figure 1A), an affinity 3.5-fold lower than
MDC1-BRCT2 (KD = 0.4 mM) when measured under the same
experimental conditions (Figure 1B), but well within the range
that is highly likely to be physiologically functional. The dephos-
phorylated H2AX peptide showed no significant binding (Fig-
ure 1A), nor did a comparable phosphopeptide from another pro-
tein (KAP1-pS824: fluorescein-GYG-SLPGAGLSpSQELSGG),
showing the interaction is both phospho-dependent and
sequence specific (Figure 1C).
Given that gH2AX is not the only phosphorylated ligand bound
specifically by other BRCT2 domains, we further defined the pa-
rameters of phosphopeptide recognition by 53BP1-BRCT2. A
gH2AX peptide with an amidated C terminus (H2AX-pS139-
NH2 or with an additional glycine (H2AX-pS139-Gly) bound
53BP1-BRCT2 far less tightly than the peptide with the free
charged a-carboxyl (Figure 1D). (Although the phosphorylated
serine in human H2AX is encoded by codon 140 of the H2AFX
gene, the initiator methionine is removed, and therefore not
generally counted in the prevalent literature. For consistency,
we here refer to this residue as Ser139.) We also explored the ef-
fect on binding to 53BP1-BRCT2 of phosphorylation of H2AX-
Tyr142, believed to mediate a switch between DNA repair and
apoptosis (Cook et al., 2009). An H2AX peptide phosphorylated
on Tyr142 bound far less tightly than the gH2AX peptide, as did a
peptide bis-phosphorylated on both Ser139 and Tyr142 (Fig-
ure 1E). These data reinforce the conclusion that the canonical
DNA-damage-responsive mark gH2AX is a specific ligand of
53BP1-BRCT2.
To further characterize the interaction, we determined the
crystal structure of 53BP1-BRCT2 in complex with the core
DNA-binding domain of P53 and a short ‘‘pSQEY’’ peptide cor-
responding to the last four residues of gH2AX (Figure 1F; Table
S1). The phosphopeptide bound in a similar conformation to its
interaction with the BRCT2 domain of MDC1, with the phosphate
group on gH2AX-Ser139 bound by the side chain of 53BP1-
Thr1737, the peptide backbone of Met1738, and the side chains
of Lys1773 and Lys1814 (Figure 1G). The side-chain carboxyl of(C) As (A) but with a fluorescein-tagged phosphopeptide derived from the major
2010). No binding was observed.
(D) As (A) but for gH2AX peptides in which the C-terminal a-carboxyl group of Tyr1
residue (open circle). Both modifications substantially reduce the affinity, and no
(E) As (A) but for H2AX peptides in which the side chain of Tyr142 is phospho
phosphorylation (open circle). In both cases, phosphorylation of Tyr142 substan
(F) Overview of crystal structure of a phosphopeptide corresponding to the last f
binding domain of P53, which is required for crystallogenesis, makes no interact
(G) Detail of interactions made by the tail of gH2AX with the 53BP1-BRCT2 doma
reflect their relative position within the protein sequence. The basic side chains of
interactions with the acidic phosphate of gH2AX-pSer139 and the a-carboxyl of
(A) and (C).
(H) As (A) but showing binding of the fluorescent gH2AX peptide to His6-SUMO
mutation (open circle).
Cell RepgH2AX-Glu141 interacts with the peptide backbone of 53BP1-
Arg1811, while the a-carboxyl of gH2AX-Tyr142 forms ionic
and hydrogen bonding interactions with the side chain of
53BP1-Arg1811, explaining the strong preference for an
unblocked C terminus in our binding assays (Figure 1D). The
side chain of Tyr142 protrudes into a hydrophobic pocket
lined by the side chains of Leu1887, Asn1883, and the main
chain of Arg1813, an interaction that would be precluded by
its phosphorylation. Consistent with the structure, charge
reversal mutation of Lys1814, which interacts with the phos-
phate on H2AX-pSer139, or Arg1811, which binds the
a-carboxyl of H2AX-Tyr142, abrogated interaction of 53BP1-
BRCT2 with the gH2AX phosphopeptide (Figure 1H). As the
BRCT2 domain of 53BP1 is a dimer in solution, like that of its
yeast homolog Crb2 (Kilkenny et al., 2008), we confirmed that
dimerization was not affected by the phospho-bindingmutations
(Figure S1).
53BP1-BRCT2 Binds gH2AX in Cells
To determine whether the in vitro interaction that we observed
for 53BP1-BRCT2 is reflected in its behavior in cells, we trans-
fected HeLa cells with an eYFPNLS-53BP1-BRCT2 construct.
Laser micro-irradiation of the nuclei of live transfected cells
caused a distinct time-dependent accumulation of fluorescence
along the laser track, consistent with recruitment of the tagged
53BP1-BRCT2 construct to sites of DNA damage; a construct
lacking the BRCT2 segment or with mutations that abolish
gH2AX binding in vitro did not (Figures 2A and 2B; Movies S1
and S2). Although it was not possible to directly image gH2AX
formation in live HeLa cells, recruitment of MDC1-BRCT2 to
the laser tracks confirms the presence of gH2AX (Movies S3),
and clear gH2AX foci could be readily visualized in fixed cells
following irradiation. The lower intensity of the recruited
53BP1-BRCT2 compared to MDC1-BRCT2 is consistent with
the lower affinity of 53BP1-BRCT2 for gH2AX we measured
in vitro. Pre-treatment of the cells with KU55933, a specific inhib-
itor of ATM, substantially diminished gH2AX focus formation on
irradiation, and this was further decreased by a DNA-PK inhibitor
NU7441 (Figure 2C). When HeLa cells expressing the eYFPNLS-
53BP1-BRCT2 construct were similarly pre-treated, recruitment
of fluorescence to the laser stripe was greatly diminished, and
with addition of NU7441, effectively abolished (Figure 2D).
Consistent with this, the eYFPNLS-53BP1-BRCT2 construct did
not localize to sites of DNA damage in mouse embryonicATM phosphorylation site on the heterochromatin protein KAP-1 (Noon et al.,
42 is modified by either amidation (closed circle) or addition of a further glycine
KD could be determined.
rylated, either alone (closed circle) or in the presence of the gH2AX Ser139
tially diminished binding to His6-SUMO-53BP1-BRCT2.
our residues of gH2AX bound to the BRCT2 domain of 53BP1. The core DNA-
ion with the gH2AX peptide and is omitted for clarity.
in. Carbon atoms in gH2AX are white; those of 53BP1 are rainbow colored to
53BP1 residues Lys1814 and Arg1811 provide neutralizing hydrogen bonding
Tyr142, which are both required for binding of gH2AX to 53BP1-BRCT2; see
-53BP1-BRCT2 with either an R1811E mutation (closed circle) or a K1814E
orts 13, 2081–2089, December 15, 2015 ª2015 The Authors 2083
(legend on next page)
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fibroblasts lacking H2AX (Figures 2E, 2F, and S2). Finally, we
immunoprecipitated the wild-type eYFPNLS-53BP1-BRCT2
construct from HeLa cell extracts and were able to detect a
co-precipitating gH2AX signal in western blots that was greatly
diminished in immunoprecipitates of eYFPNLS-53BP1-BRCT2
with the R1811E mutation that abrogates gH2AX binding
in vitro (Figure 2G).
Taken together, these structural, biochemical, and cellular ob-
servations provide compelling evidence that the BRCT2 segment
of 53BP1 has an inherent ability to localize to sites of DNA dam-
age independently of other regions of the protein, and that this
recruitment, which depends on phosphorylation of H2AX by
DNA-damage-responsive PIKK kinases, is mediated by the
clearly demonstrated ability of 53BP1-BRCT2 to bind gH2AX
both specifically and directly.
Phospho-Binding by 53BP1-BRCT2 Regulates pATM
Focal Localization
Having demonstrated the ability of 53BP1 to bind gH2AX
directly, we sought to determine whether this ability contributed
to any of the known roles of 53BP1 in the DNA damage
response.
53BP1 is required for the focal localization of activated ATM,
autophosphorylated on Ser1981 (Bakkenist and Kastan, 2003),
and MRE11-RAD50-NBS1 (MRN) complexes at sites of DNA
damage, and in the consequent activation of ATM checkpoint
signaling (DiTullio et al., 2002; Mochan et al., 2004; Lee et al.,
2010; Panier and Boulton, 2014). Consistent with this, small
interfering RNA (siRNA) knockdown of 53BP1 in HeLa cells
substantially diminished recruitment of activated pATM and
MRN (visualized by NBS1), to nuclear ionizing radiation-
induced foci (IRIF), with both of these proteins displaying a
diffuse pan-nuclear distribution following irradiation (Figures 3
and S3).
Wild-type siRNA-resistant HA-tagged 53BP1 expressed in
these knockdown cells, formed distinct foci itself following irra-
diation, and restored NBS1 and pATM foci that co-localized
with those of 53BP1. However, a 53BP1 construct completely
lacking the BRCT2 domain still formed foci of its own but failed
to restore NBS1 and pATM foci. By contrast 53BP1 constructs
in which the BRCT2 domain was present but contained muta-Figure 2. 53BP1 BRCT2 Domain Localizes to DNA Damage through Ph
(A) HeLa cells were reverse transfected with 53BP1 siRNA. 48 hr later, cells were
containing either wild-type or mutant BRCT domains, or eYFP-SV40NLS-MDC1-B
line indicated by the white arrowheads, and images were recorded over 3 min. S
(B) eYFP fluorescence was tracked over 3 min to observe localization. Profiles
Slidebook6 software (n = 30 from three experimental repeats). Error bars, 1 SD.
(C) Cells were treated with either KU55933 (ATMi), NU7441 (DNA-PKi), or both for
before fixing and staining for gH2AX. Scale bar, 10 mm.
(D) Cells were processed as before with the addition of either DNA-PKi, ATMi, o
over 3 min to observe localization. Fluorescence intensity profiles were generat
bars, 1 SD.
(E) H2AX+/+ and H2AX/ mouse embryonic fibroblasts were reverse transfecte
SV40NLS-53BP1-BRCT2 construct or the eYFP-SV40NLS control. 16 hr after thi
tracked over 3 min to observe localization. Scale bar, 10 mm.
(F) Fluorescence intensity profiles from (E) were generated using Slidebook6 sof
(G) eYFP-SV40NLS-53BP1-BRCT2 was immunoprecipitated using GFP-trap bea
eYFP-SV40NLS-53BP1-BRCT2 or gH2AX detected by western blot. Inputs repres
Cell Reptions that disrupt binding to gH2AX (R1811E, K1814E) were
able to recruit NBS1 into co-incident foci but had no effect
on pATM, which retained the diffuse staining evident in the
53BP1 knockdown cells. A defect in pATM focus formation
was evident with the K1814E mutant as early as 30 min post-
irradiation (Figure S3B). A 53BP1 construct with a Tudor
domain mutation (Y1502L) that abolishes recruitment to DNA
damage (Huyen et al., 2004; Botuyan et al., 2006) eliminated
53BP1 foci and did not restore focal concentration of either
NBS1 or pATM.
These data confirm previous observations that 53BP1 facili-
tates focal concentration of NBS1 (and thereby MRN) and
pATM at DNA breaks in G1 but show that in both cases
this is dependent on the BRCT2 domain, and that focal recruit-
ment of pATM is specifically dependent on the ability of that
domain to interact with gH2AX. These data also indicate a
function for the 53BP1-BRCT2 in mediating an additional
link between MRN complexes and chromatin modification,
via its phosphorylation-independent interaction with RAD50
(Paull, 2015) and its phosphorylation-dependent interaction
with gH2AX.
Phospho-Binding by 53BP1-BRCT2 Contributes to
Heterochromatin Repair
Double-strand break (DSB) repair in heterochromatin occurs
more slowly than in euchromatin and requires 53BP1-depen-
dent retention of pATM and consequent phosphorylation of
the silencing factor KAP1/TRIM28 (Noon et al., 2010), which
promotes its release with consequent relaxation of the
heterochromatin. HeLa cells contact-inhibited in G0/G1, and
transfected with 53BP1 siRNA, displayed significantly higher
numbers of gH2AX foci 16–24 hr after irradiation than mock-
transfected cells, or knockdown cells expressing a wild-type
53BP1 construct (Figure 4A). Consistent with their inability to
localize pATM (Figure 3B), 53BP1 constructs lacking the
BRCT2 domain or with gH2AX-binding defective mutations
failed to rescue the knockdown phenotype and resulted in
significantly increased levels of gH2AX foci at later time points
(Figures 4B and S4). Simultaneous knockdown of KAP1, whose
phosphorylation depends on pATM localization, reduced the
number of persistent gH2AX foci seen with these mutantsospho-Specific Interactions
transfected with eYFP-SV40NLS or eYFP-SV40NLS-53BP1-BRCT2 constructs
RCT2. 16 hr after this cells were damaged using laser micro-irradiation along a
cale bar, 10 mm.
of fluorescence intensity along the laser track in (A) were generated using
1 hr prior to irradiation with 3 Gy of IR. Cells were incubated for a further 30 min
r both for 1 hr prior to laser micro-irradiation. eYFP-fluorescence was tracked
ed using Slidebook6 software (n = 30 from three experimental repeats). Error
d with 53BP1 siRNA. 24 hr later, cells were transfected with either the eYFP-
s, cells were damaged using laser micro-irradiation. eYFP fluorescence was
tware (n = 30 from three experimental repeats). Error bars, 1 SD.
ds (ChromoTek), from benzonase-treated, g-irradiated HeLa cell lysates, and
ent 1/1,000 of the total sample used in the immunoprecipitation.
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Figure 3. Co-localization of pATM Is Dis-
rupted in 53BP1-BRCT2 Phospho-Binding
Mutants
(A) HeLa cells were reverse transfected with
53BP1 siRNA. 48 hr later, cells were transfected
with an siRNA-resistant construct containing wild-
type HA-53BP1, one of the BRCT mutants, or a
Tudor domain mutant (Y1502L). 16 hr after this,
cells were exposed to either 8 Gy for mock and
wild-type (WT) or 3 Gy of ionizing radiation for the
mutants and allowed to recover for 24 hr before
staining for HA and NBS1. Scale bar, 5 mm.
(B) As (A) but stained for pATM.
(C) Cells processed in (A) and (B) were analyzed by
measuring foci intensity of HA, pATM, and NBS1
(n = 30). Foci intensities were normalized to the
average wild-type foci intensity for their respective
channel. Normalized HA foci intensities from cells
transfected with either WT or BRCT mutants in-
dicates comparable expression of the plasmid
constructs. Graph shows average of three exper-
iments with 1 SD.back down to wild-type levels (Figure 4C), confirming that these
persistent foci were due to damage sites in heterochromatin
(Goodarzi et al., 2008).
Biological Roles of 53BP1 Binding to gH2AX
To date, BRCT2 domains of three mammalian proteins—
MCPH1, PTIP, and MDC1—have been found to specifically
recognize the primary mark of DNA damage, gH2AX (Yan
et al., 2011; Stucki et al., 2005; Singh et al., 2012). Our
data show unambiguously that this is a property shared2086 Cell Reports 13, 2081–2089, December 15, 2015 ª2015 The Authorsby the BRCT2 domain of 53BP1, and
that this interaction plays a role in the
biological functions of 53BP1—a very
similar conclusion was reached by
Kleiner et al. (2015). This observation
further strengthens the idea that 53BP1
is the functional ortholog of the fission
yeast and budding yeast proteins Crb2
and Rad9p (Hammet et al., 2007; Kil-
kenny et al., 2008).
Although the ability of the BRCT2
domain of 53BP1 to bind gH2AX contrib-
utes to efficient repair of DNA damage, it
is not required for initial recruitment of
53BP1 to IRIF in the immediate response
to DNA damage in G1. 53BP1 recruitment
is downstream of recognition of gH2AX
by MDC1, whose BRCT2 domain has a
higher affinity for gH2AX. Nonetheless,
once recruited to damaged chromatin
53BP1’s interaction with gH2AX would
be favored by its interaction with the other
post-translational modifications it recog-
nizes, and the gH2AX interaction might
only become functionally significant at a
later stage of the IRIF-centered repairprocesses or in specific situations such as the repair of damage
in heterochromatin, as we show here.
Recruitment and retention of 53BP1 at sites of DNA damage
facilitates co-localization and retention of other factors required
for signaling and repair (Panier and Boulton, 2014). In the case of
MRN, this is mediated by a phospho-independent interaction
between RAD50 and the 53BP1-BRCT2 (Lee et al., 2010). Re-
gions within the MRN complex have, in turn, been implicated in
recruiting and activating ATM at sites of DNA damage (Paull,
2015), but it is not clear what role these play in retaining pATM
Figure 4. Slow Repair of Damage in Hetero-
chromatin Is Defective in 53BP1-BRCT2
Phospho-Binding Mutants
(A) HeLa cells were reverse transfected with
53BP1 siRNA. 48 hr later, cells were transfected
with an siRNA-resistant construct containing wild-
type HA-tagged 53BP1 or one of the BRCT mu-
tants. 16 hr later, cells were exposed to 3 Gy of
ionizing radiation and allowed to recover for the
indicated time before staining for HA-53BP1 and
gH2AX. Higher numbers of gH2AX foci were
evident 24 hr after irradiation in siRNA-treated cells
and siRNA-treated cells transfected with 53BP1
mutant constructs.
(B) Quantitation of gH2AX focus persistence.
Graphs show the mean of three experiments; error
bars, 1 SD. 53BP1 constructs lacking the BRCT
domain or with point mutations that abrogate
gH2AX binding in vitro show significantly higher
levels of persistent gH2AX foci than wild-type
(one-way ANOVA).
(C) As (A) but with 53BP1 and/or KAP-1 siRNA.
Persistence of significantly higher levels of gH2AX
foci in the presence of 53BP1 mutants is sup-
pressed when KAP-1 is also knocked down, indi-
cating that persistence is due to a defect in KAP-1
phosphorylation by ATM as a result of the failure of
the 53BP1 mutants to localize pATM to hetero-
chromatinized sites of damage.in damage foci downstream of initial activation. Our data indicate
that focal concentration and retention of pATM at slowly repaired
sites of DNA damage in G1 (Noon et al., 2010) is independent of
MRN recruitment but dependent on 53BP1 recruitment and,Cell Reports 13, 2081–2089, Designificantly, the histone modifications it
engages with. Thus, while removal of the
ability of 53BP1 to bind gH2AX does not
affect focal co-localization of MRN and
53BP1, it substantially reduces pATM
localization, which, in turn, results in a
defect in DSB repair in heterochromatin.
These data highlight a role for the
53BP1-BRCT2 domain in reinforcing links
between MRN complexes and chromatin
modification, via its phosphorylation-
independent interaction with RAD50
(Noon et al., 2010) and its phosphoryla-
tion-dependent interaction with gH2AX.
The means by which 53BP1 facilitates
pATM concentration and retention in
IRIFs remains unclear. There is little indi-
cation in the literature of a direct interac-
tion of ATM with 53BP1, although both
proteins have well-documented interac-
tions with other proteins in common.
The dependence we demonstrate here
on 53BP1’s ability to bind gH2AX sug-
gests that this is likely to involve complex
features of local chromatin conformation
and histone modifications and furtherwork will be required to define this. It is highly likely that other
of the myriad functions of 53BP1 will also involve this hitherto
disregarded property of 53BP1, and work is ongoing to uncover
and characterize these.cember 15, 2015 ª2015 The Authors 2087
EXPERIMENTAL PROCEDURES
See the Supplemental Experimental Procedures for full details.
Protein Expression and Purification
Proteins for biochemical and structural analysis were expressed in E. coli and
purified by affinity and conventional chromatography.
Fluorescence Polarization Experiments
Binding to BRCT2 domains was determined using fluorescein-labeled pep-
tides and His6-SUMO-BRCT2 fusion proteins. Dissociation constants (KD)
were determined by non-linear regression to a one site-specific bindingmodel.
Crystallization, X-Ray Diffraction Data Collection, Phasing, Model
Building, and Refinement
Crystals of P53Core/53BP1-BRCT2 were grown by vapor diffusion and
soaked with the gH2AX-pS139 peptide (pSQEY) for 60 min prior to plunge-
freezing in liquid nitrogen. Diffraction data were collected at the Diamond
Synchrotron Lightsource, and the structure was determined by molecular
replacement.
Tissue Culture, Cell Lines, and Reagents
HeLa, H2AX+/+, and H2AX/ mouse embryonic fibroblast (MEF) cells were
cultured in DMEM supplemented with 10% (v/v) fetal calf serum (FCS), peni-
cillin, streptomycin, and L-glutamine. Caffeine (Sigma-Aldrich) was used at a
final concentration of 10 mM. ATMi (KU55933, Abcam), DNA-PKi (NU7441,
Santa Cruz Biotechnology), and ATRi (ATR-kinase inhibitor II, Merck Millipore)
were all used at a concentration of 10 mM, except for the CHK1 inhibitor UCN-
01 (Sigma-Aldrich) that was used at a concentration of 200 nM. Cells were irra-
diated using a Caesium137 gamma source.
siRNA Depletion of 53BP1/KAP-1 and siRNA-Resistant Expression
of 53BP1
HeLa cells were seeded at high confluence onto 35-mm plates and reverse
transfected with either 53BP1-siRNA or negative control oligonucleotides
diluted into serum free media Cells were cultured for a further 48 hr for efficient
depletion. Subsequently cells were transfected with 53BP1 constructs
rendered siRNA-resistant by three silent point mutations in the 53BP1 cDNA
clone in pCMH6K (A231G, A234G, and A237C) (Noon et al., 2010) and incu-
bated for a further 16 hr before irradiation.
Antibodies
All antibodies used were from standard commercial sources (see the Supple-
mental Experimental Procedures for full details).
Immunofluorescence
Cells were fixed on coverslips and washed three times before incubation at
room temperature with the primary antibodies. Cells were washed a further
three times before incubation with the secondary, fluorophore-coupled, anti-
bodies, and washed a final three times before mounting on glass slides with
DAPI mounting media.
Live-Cell Imaging and UV-Laser Microirradiation
Cells were seeded at low confluence before 53BP1 depletion by siRNA, and
eYFP-SV40NLS-53BP1-BRCT2 plasmid constructs were transfected into cells.
Cells were incubated for 20 min with 100 mg/ml Hoechst 34580 prior to excita-
tion with a 405-nm laser. Protein localization was tracked over 3 min using a
488-nm laser.
GFP-Trap
Stable cell lines were generated for HeLa cells transfected with wild-type or
R1811E mutant forms of the eYFP-SV40NLS-53BP1-BRCT2 expression
construct. Cellular lysates were generated by re-suspension of frozen pellets,
and incubated with GFP-Trap A resin. Retained protein was detected by
chemiluminescent western blot.2088 Cell Reports 13, 2081–2089, December 15, 2015 ª2015 The AuACCESSION NUMBERS
The accession number for the crystallographic data reported here is PDB:
5ECG.
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SUPPLEMENTARY TABLE 1. Crystallographic Data Collection and Refinement 
Statistics – Relates to FIGURE 1 
* Statistics for the highest-resolution shell are shown in parentheses 
 
 
 
Data Collection 
 
Wavelength (Å) 0.9173 
Resolution range (Å) 48.06 - 3.0 (3.107  - 3.0)* 
Space group  P 21 21 21 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
70.26, 94.50,131.74  
90, 90, 90 
Total reflections 77558 (7954) 
Unique reflections 18110 (1778) 
Multiplicity 4.3 (4.5) 
Completeness (%) 99.66 (99.83) 
Mean I / σ(I)                     12.57 (1.40) 
Wilson B-factor 77.04 
Rmerge 0.1044 (1.057) 
CC1/2 0.997 (0.563) 
CC* 0.999 (0.849) 
 
Refinement 
 
 
Reflections used for R-free  
Rwork 0.2053 (0.3441) 
Rfree 0.2512 (0.4353) 
Number of non-hydrogen atoms 6537 
macromolecules 6473 
ligands 9 
water 56 
Protein residues 854 
RMS bond-lengths 0.014 
RMS bond-angles 1.80 
Ramachandran favored (%)                               92 
Ramachandran allowed (%) 6.4 
Ramachandran outliers (%) 1.6 
Clashscore 4.68 
Average B-factor 88.6 
macromolecules 88.9 
ligands 85.4 
solvent 63.4 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Protein Expression and Purification 
His6-SUMO-53BP1-BRCT2 and His6-SUMO-MDC1-BRCT2 were expressed from a 
modified pET-15b vector (EMD-Millipore, Darmstadt, Germany) in Escherichia 
coli BL21(DE3) (Novagen). Cell pellets were re-suspended in lysis buffer containing 
50mM HEPES pH 7.5, 300mM NaCl, 0.25mM TCEP, 10% w/v glycerol, then 
disrupted by sonication, and the resulting lysate clarified by centrifugation at 40,000 x 
g for 60 minutes at 4°C. The supernatant was applied to a 5ml HiTrap TALON crude 
column (GE Healthcare, Little Chalfont, UK), washed with buffer containing 50mM 
HEPES pH 7.5, 300mM NaCl, 0.25mM TCEP, 10mM imidazole, with any retained 
protein then eluted by application of the same buffer but now supplemented with 
250mM imidazole.  
For FP experiments, a Superdex 75 16/60 size exclusion column (GE Healthcare) 
was used to purify the His6-SUMO-53BP1-BRCT2 and His6-SUMO-MDC1-BRCT2 
proteins to homogeneity in 25mM HEPES pH 7.5, 200mM NaCl, 1mM EDTA, 
0.25mM TCEP, 0.02% (v/v) Tween-20. 
For crystallographic studies, the N-terminal metal affinity and solubility tag (His6-
SUMO) was removed from the His6-SUMO-53BP1-BRCT2 by incubation with GST-
SENP1c protease (in house) for 12 hours at 4°C. A Superdex 75 16/60 size 
exclusion column (GE Healthcare) was used to purify 53BP1-BRCT2 to homogeneity 
in 20mM HEPES pH 7.5, 200mM NaCl, 0.25mM TCEP. 
GST-P53Core was expressed from a modified pGEX-6P-1 vector (EMD-Millipore) in E. 
coli BL21(DE3).  Cell pellets were re-suspended in lysis buffer containing 50mM 
HEPES pH 7.5, 300mM NaCl, 2.5mM EDTA, 0.25mM TCEP, 10% w/v glycerol, then 
disrupted by sonication, and the resulting lysate clarified by centrifugation at 40,000 x 
g for 60 minutes at 4°C.  The supernatant was applied to a 5 ml GSTrap FF column 
(GE Healthcare), washed with lysis buffer and then eluted by application of the same 
buffer but now supplemented with 20mM Glutathione. The N-terminal GST affinity 
tag was removed by incubation with Human rhinovirus-3C protease (in house) for 12 
hours at 4°C. A Superdex 75 16/60 size exclusion column (GE Healthcare) was used 
to purify P53Core to homogeneity in 20mM HEPES pH 7.5, 200mM NaCl, 0.25mM 
TCEP. 
To produce the P53Core / 53BP1-BRCT2 complex, 53BP1-BRCT2 was mixed with a 
slight molar excess of P53Core and the resulting complex purified using a Superdex 
75 16/60 size exclusion column (GE Healthcare) in 20mM HEPES pH 7.5, 200mM 
NaCl, 0.25mM TCEP. 
Fluorescence Polarisation Experiments 
Fluorescein-labelled peptides (Peptide Protein Research Ltd, Bishops Waltham, UK) 
at a concentration of 200nM, were incubated at room temperature with increasing 
concentrations of His6-SUMO-53BP1-BRCT2 in 25mM HEPES pH 7.5, 200mM NaCl, 
1mM EDTA, 0.25mM TCEP, 0.02% (v/v) Tween-20 in a black 96-well polypropylene 
plate (VWR, Lutterworth, UK).  Fluorescence polarisation was measured in a 
POLARstar Omega multimode microplate reader (BMG Labtech GmbH, Offenburg, 
Germany).  Binding curves represent the mean of 4 independent experiments, with 
error bars of 1 standard deviation.  All data were fitted by non-linear regression, to a 
one site – specific binding model in Prism 6 for Mac OS X (v 6.0d, GraphPad 
Software) in order to calculate the reported disassociation constants (Kd). 
 
Crystallisation, X-ray Diffraction Data Collection, Phasing, Model Building and 
Refinement 
Co-crystallisation trials of the P53Core / 53BP1-BRCT2 complex were set up in MRC 2 
96-well sitting-drop vapour-diffusion plates by mixing 200nl of 12mg/ml protein 
solution with 200nl of mother, over a well volume of 50µl. Crystals that grew from 
condition F1 (200mM NaF, 100mM Bis-Tris Propane pH 6.5, 20% (w/v) PEG 3,350) 
of the PACT premier HT-96 (Molecular Dimensions, Newmarket, UK) screen, were 
soaked in mother liquor with the addition of both 20% (v/v) PEG 400 and 20µM 
γH2AX-pS139 peptide (pSQEY) for 60 minutes prior to plunge-freezing in liquid 
nitrogen. 
Diffraction data were collected at the I04-1 beamline at the Diamond Synchrotron 
Lightsource (Didcot, UK) and auto-processed using the Xia2 software pipeline. The 
structure was determined by molecular replacement using Phaser (McCoy et al., 
2007) with PDB entry 1KZY as a search model. The structure was built using COOT 
(Emsley et al., 2010) and refined with Phenix (Zwart et al., 2008). 
Tissue Culture, Cell lines and Reagents 
HeLa, H2AX+/+ and H2AX-/- MEF cells were cultured in DMEM supplemented with 
10% (v/v) FCS, penicillin, streptomycin and L-glutamine.  Caffeine (Sigma-Aldrich, 
Gillingham, UK) was used at a final concentration of 10mM. ATMi (KU55933, Abcam, 
Cambridge, UK), DNA-PKi (NU7441, Santa Cruz Biotechnology, Heidelberg, 
Germany) and ATRi (ATR-kinase inhibitor II, Merck-Millipore) were all used at a 
concentration of 10µM, except for the CHK1 inhibitor UCN-01 (Sigma-Aldrich) that 
was used at a concentration of 200nM. Cells were irradiated using a Caesium137 
gamma source.    
 
siRNA depletion  of 53BP1/KAP-1 and siRNA-resistant expression of 53BP1 
HeLa cells were seeded at high confluence onto 35mm plates and reverse 
transfected with either  53BP1-siRNA or a negative control - Stealth RNAi (Life 
Technologies, Paisley, UK). Cells were transfected using Hiperfect (Qiagen, 
Manchester, UK) with oligonucleotides diluted into OptiMEM serum free media (Life 
Technologies) and to a final concentration of 20nM. 53BP1-siRNA oligonucleotides 
used: 5’-AGAACGAGGAGACGGUAAUAGUGGG-3’ and 5’ 
CCCACUAUUACCGUCUCCUCGUUCU 3’ (Invitrogen). Cells were cultured for a 
further 48 hours for efficient depletion. Following this cells were washed in 1xPBS 
before transfection with siRNA-resistant 53BP1 constructs using NanoJuice Core 
Transfection Reagent (Merck-Millipore) and booster at a ratio of 3:1 (Reagent:DNA). 
Resistance to siRNA was conferred by 3 silent point mutations in the 53BP1 cDNA 
clone in pCMH6K (A231G, A234G and A237C) (Noon et al., 2010). Each plate was 
transfected with 1.5µg of plasmid DNA. Cells were incubated for a further 16 hours to 
allow cells to express the plasmid before irradiation. For dual depletion of both 
53BP1 and KAP1, both oligonucleotides were transfected at a final concentration of 
20nM. KAP1 siRNA oligonucleotides used: 5’ GCGGAAAUGUGAGCGUGUAtt 3’ and 
5’ UACACGCUCACAUUUCCGCtg 3’ (Life Technologies).  
 
Antibodies  
Dilutions shown refer to immunofluorescence unless otherwise stated: α-HA probe 
mouse monoclonal (Santa Cruz Biotechnology) at 1:200, α-phosphorylated ATM 
(S1981) rabbit monoclonal (Abcam, ab81292) at 1:400, α-γH2AX (S139) rabbit 
polyclonal (Merck-Millipore, DR1017) at 1:400, α-γH2AX (S139) mouse monoclonal 
(Merck-Millipore, 05-636) at 1:800, α-53BP1 rabbit polyclonal (Bethyl Laboratories, 
Montgomery, TX, USA, A300-272A) at 1:400 for IF and 1:5000 for WB, α-BRCA1 
mouse monoclonal (Santa Cruz Biotechnology, sc-642) at 1:100, α-NBS1 rabbit 
polyclonal (Novus, Abingdon, UK, NB100-143) at 1:500, α-ATR (Santa Cruz 
Biotechnology, Sc-1887) and α-KAP1 (Abcam, a10484) at 1:2500 for WB. Secondary 
antibodies used were: HRP-rabbit (Cell Signaling Technology, Danvers, MA, USA) at 
1:2500 for WB, FITC-mouse (Sigma-Aldrich), TritC-Rabbit (Sigma-Aldrich) and Cy5-
Rabbit (Life Technologies) all used at 1:200.  
 
Immunofluorescence 
Cells cultured on coverslips were fixed using 4% (w/v) PFA in PBS for 10 minutes 
and permeablised using 0.1% (v/v) Triton-X100 in PBS for 30 seconds. Cells were 
washed 3 times with PBS before incubation for 1 hour at room temperature with the 
primary antibodies diluted to the indicated concentration in 4% (w/v) BSA in PBS.  
Cells were washed a further 3 times with PBS before incubation for 30 minutes with 
the secondary, fluorophore-coupled, antibodies. Secondary antibodies were diluted 
as before in 4% (w/v) BSA in PBS. Cells were washed a final 3 times before 
mounting on glass slides with ProLong Gold with DAPI mounting media (Life 
Technologies).  
 
Live cell imaging and UV-laser microirradiation 
Cells were seeded at a lower confluence before 53BP1 depletion by siRNA and 
eYFP-SV40NLS-53BP1-BRCT2 plasmid constructs were transfected into cells using 
NanoJuice as before. Cells were incubated for 20 minutes with 100µg/ml Hoecsht 
34580 (Scientific Laboratory Supplies, Hessle, UK, 63493) prior to excitation with a 
405nm laser. Protein localisation was tracked over 3 minutes using a 488nm laser. 
 
	  
GFP-Trap  
Stable cell lines were generated by G418 antibiotic selection for HeLa cells 
transfected with wild-type or R1811E mutant forms of the eYFP-SV40NLS-53BP1-
BRCT2 expression construct.  
Irradiated cells were: harvested by scraping 4 x 20cm petri dishes - seeded at 1.8 x 
105 cells / ml and grown in 30ml of DMEM medium with G418 selection (400µg/ml) 
for 48 hours at 37°C in a 5% CO2 environment – into PBS buffer, pelleted by 
centrifugation, and then stored at -20°C.  
Cellular lysates were generated by re-suspension of the frozen cell pellets in 2ml of 
RIPA buffer (Sigma-Aldrich) supplemented with EDTA-free protease- and PhosSTOP 
phosphatase-inhibitor tablets (Roche Diagnostics, Burgess Hill, UK) and 40µl 
Benzonase endonuclease (25 Units/µl, Merck-Millipore), followed by disruption in a 
Bioruptor Pico with water cooler (Diagenode, Seraing, Belgium).  Cell debris and 
insoluble material were removed by centrifugation at 16,000 x g, for 10 minutes at 
4°C, followed by dilution in 10mM Tris-HCl pH 7.5, 150mM NaCl, 0.5mM EDTA, 
0.5mM TCEP supplemented with protease and phosphatase inhibitor tablets as 
before, to a final volume of 10ml.  The diluted supernatant was then incubated with 
~200µl bed volume of GFP-Trap_A resin (Chromotek, Planegg-Martinsried, Germay) 
following the manufacturer’s recommended protocol.  After binding and washing of 
the beads with dilution buffer, any retained protein was detected by chemi-
luminescent western blot, following SDS-PAGE separation and transfer to a 
nitrocelluose membrane.  Antibodies used: rabbit polyclonal anti-GFP (2555S, Cell 
Signaling), donkey anti-rabbit IgG-HRP conjugate (NA934V, GE Healthcare), mouse 
monoclonal anti-phospho-Histone H2AX(Ser139) (JBW301, Merck-Millipore), sheep 
anti-mouse IgG-HRP conjugate (NXA931, GE Healthcare). 	  
SUPPLEMENTARY FIGURE LEGENDS 
 
FIGURE S1 - Gel Filtration analysis of wt and point-mutant 53BP1-
BRCT2 constructs – relates to FIGURE 1 
 
Elution profiles for 53BP1-BRCT2 constructs with/without His6-SUMO tag 
used for purification. Regardless of the presence of point-mutations that 
disrupt the ability of the BRCT2 domain to bind γH2AX, the proteins elute from 
a calibrated gel filtration column at positions consistent with dimers of the 
predicted monomer molecular weight. 
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FIGURE S2 - γH2AX staining in MEFs - relates to FIGURE 2 
 
 
 
Immunofluorescence staining for γH2AX in mouse embryonic fibroblast lines 
with. No γH2AX response is seen in H2AX -/- cells. 
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FIGURE S3 - 53BP1 siRNA knock down and effect of 53BP1 mutants on 
focus formation - relates to FIGURE 3 
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A) Western blot of HeLa cells confirming substantial knock-down of 
53BP1 protein levels in siRNA treated cells. 
B) Immunofluorescence staining 30 minutes post irradiation for HA-
53BP1 and pATM in γ-irradiated HeLa cells that were : mock 
transfected, transfected with 53BP1 siRNA, siRNA treated and 
transfected with an siRNA-resistant wild-type HA-53BP1 or a 
K1814E mutant 53BP1. 
C) As B) but visualized 60 minutes post-irradiation. 
 
FIGURE S4 - 53BP1 and KAP1 siRNA knock-downs and focus γH2AX 
focus persistence - relates to FIGURE 4 
 
 
Western blot of HeLa cells confirming substantial knock-downs of 53BP1 and 
KAP1 protein levels in siRNA treated cells. 
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SUPPLEMENTARY MOVIES 
 
MOVIE S1 – Example time-lapse of fluorescence microscope field of HeLa 
cells showing of eYFP-MDC1-BRCT2 recruitment to laser stripe damage; 
positive control for formation of DNA double-strand breaks and γH2AX by 
laser microirradiation. Crosshairs mark start and end of laser path(s). Relates 
to FIGURE 2 
MOVIE S2 – As S1 but for eYFP-NLS-53BP1-BRCT2 showing wild-type 
BRCT2 mediates recruitment to DNA damage. Relates to FIGURE 2 
MOVIE S3 – As S3 but for eYFP-NLS-53BP1-BRCT2 with K1814E mutation, 
which abrogates interaction with γH2AX and prevents recruitment to laser 
stripe. Relates to FIGURE 2 
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